Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetesCATT1 Phase 3 trial expected to resume following ...

Magnesium regulates an enzyme known as glucokinase, responsible for converting glucose into glucose-6-phosphate. Type 2 ...

All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial ...

Cadisegliatin is an oral, liver-selective glucokinase activator that has been generally well tolerated in over 500 subjects to date with up to six months of treatment. vTv Therapeutics expects to ...